What is Haemonetics Corp Mass's earnings per share (EPS)?

Haemonetics Corp Mass (HAE) reported diluted earnings per share of $3.31 for fiscal year 2025. This represents a 44.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Haemonetics Corp Mass Financials

HAE

Source SEC Filings (10-K/10-Q) Updated Dec 27, 2025 Currency USD FYE March

This page shows Haemonetics Corp Mass (HAE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 52/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Haemonetics Corp Mass has an operating margin of 16.3%, meaning the company retains $16 of operating profit per $100 of revenue. This results in a moderate score of 58/100, indicating healthy but not exceptional operating efficiency. This is up from 12.6% the prior year.

Growth

Haemonetics Corp Mass's revenue grew a modest 4.0% year-over-year to $1.4B. This slow but positive growth earns a score of 40/100.

Leverage

Haemonetics Corp Mass carries a low D/E ratio of 1.12, meaning only $1.12 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 79/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Haemonetics Corp Mass's current ratio of 1.62 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 28/100, which could limit financial flexibility.

Cash Flow

Haemonetics Corp Mass has a free cash flow margin of 10.5%, earning a moderate score of 51/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

Haemonetics Corp Mass's ROE of 20.4% shows moderate profitability relative to equity, earning a score of 57/100. This is up from 12.3% the prior year.

Altman Z-Score Grey Zone

2.20

Haemonetics Corp Mass scores 2.20, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.

Piotroski F-Score Neutral

6/9

Haemonetics Corp Mass passes 6 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

1.08x

For every $1 of reported earnings, Haemonetics Corp Mass generates $1.08 in operating cash flow ($181.7M OCF vs $167.7M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

6.2x

Haemonetics Corp Mass earns $6.2 in operating income for every $1 of interest expense ($221.8M vs $35.9M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.4B

YoY+4.0%

5Y CAGR+6.6%

10Y CAGR+4.1%

Haemonetics Corp Mass generated $1.4B in revenue in fiscal year 2025. This represents an increase of 4.0% from the prior year.

EBITDA

$337.4M

YoY+28.7%

5Y CAGR+9.6%

10Y CAGR+10.3%

Haemonetics Corp Mass's EBITDA was $337.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 28.7% from the prior year.

Net Income

$167.7M

YoY+42.6%

5Y CAGR+17.0%

10Y CAGR+25.8%

Haemonetics Corp Mass reported $167.7M in net income in fiscal year 2025. This represents an increase of 42.6% from the prior year.

EPS (Diluted)

$3.31

YoY+44.5%

5Y CAGR+17.5%

10Y CAGR+26.3%

Haemonetics Corp Mass earned $3.31 per diluted share (EPS) in fiscal year 2025. This represents an increase of 44.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$142.4M

YoY-0.8%

5Y CAGR+5.4%

10Y CAGR+39.9%

Haemonetics Corp Mass generated $142.4M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 0.8% from the prior year.

Cash & Debt

$306.8M

YoY+71.6%

5Y CAGR+17.4%

10Y CAGR+6.7%

Haemonetics Corp Mass held $306.8M in cash against $921.2M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

48M

YoY-5.2%

5Y CAGR-0.9%

10Y CAGR-0.7%

Haemonetics Corp Mass had 48M shares outstanding in fiscal year 2025. This represents a decrease of 5.2% from the prior year.

Margins & Returns

Gross Margin

55.0%

YoY+2.2pp

5Y CAGR+6.0pp

10Y CAGR+7.3pp

Haemonetics Corp Mass's gross margin was 55.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 2.2 percentage points from the prior year.

Operating Margin

16.3%

YoY+3.7pp

5Y CAGR+5.8pp

10Y CAGR+11.9pp

Haemonetics Corp Mass's operating margin was 16.3% in fiscal year 2025, reflecting core business profitability. This is up 3.7 percentage points from the prior year.

Net Margin

12.3%

YoY+3.3pp

5Y CAGR+4.6pp

10Y CAGR+10.5pp

Haemonetics Corp Mass's net profit margin was 12.3% in fiscal year 2025, showing the share of revenue converted to profit. This is up 3.3 percentage points from the prior year.

Return on Equity

20.4%

YoY+8.2pp

5Y CAGR+7.4pp

10Y CAGR+18.4pp

Haemonetics Corp Mass's ROE was 20.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 8.2 percentage points from the prior year.

Capital Allocation

R&D Spending

$62.7M

YoY+15.2%

5Y CAGR+15.2%

10Y CAGR+1.5%

Haemonetics Corp Mass invested $62.7M in research and development in fiscal year 2025. This represents an increase of 15.2% from the prior year.

Share Buybacks

$225.0M

5Y CAGR+5.2%

10Y CAGR+19.1%

Haemonetics Corp Mass spent $225.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

$39.3M

YoY+3.0%

5Y CAGR-4.2%

10Y CAGR-10.7%

Haemonetics Corp Mass invested $39.3M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 3.0% from the prior year.

HAE Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$1.4B+4.0%	$1.3B+12.0%	$1.2B+17.7%	$993.2M+14.1%	$870.5M-11.9%	$988.5M
Cost of Revenue	$611.9M-0.9%	$617.5M+11.6%	$553.6M+13.5%	$487.7M+3.2%	$472.6M-6.2%	$504.0M
Gross Profit	$749.0M+8.3%	$691.5M+12.4%	$615.1M+21.7%	$505.5M+27.1%	$397.8M-17.9%	$484.5M
R&D Expenses	$62.7M+15.2%	$54.4M+8.6%	$50.1M+7.1%	$46.8M+42.4%	$32.9M+6.4%	$30.9M
SG&A Expenses	$436.8M+1.2%	$431.8M+14.6%	$376.7M+10.7%	$340.1M+23.6%	$275.2M-2.4%	$282.0M
Operating Income	$221.8M+34.5%	$164.9M+5.7%	$156.0M+93.2%	$80.8M-10.0%	$89.7M-13.2%	$103.4M
Interest Expense	$35.9M+84.1%	$19.5M+50.0%	$13.0M+124.1%	$5.8M-38.3%	$9.4M-30.4%	$13.5M
Income Tax	$44.4M+29.4%	$34.3M+31.9%	$26.0M+28.4%	$20.3M+408.9%	-$6.6M-161.7%	$10.6M
Net Income	$167.7M+42.6%	$117.6M+1.9%	$115.4M+166.1%	$43.4M-45.4%	$79.5M+3.8%	$76.5M
EPS (Diluted)	$3.31+44.5%	$2.29+2.2%	$2.24+166.7%	$0.84-45.8%	$1.55+4.7%	$1.48

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Revenue	$339.0M+3.6%	$327.3M+1.8%	$321.4M-2.8%	$330.6M-5.1%	$348.5M+0.9%	$345.5M+2.8%	$336.2M-2.1%	$343.3M
Cost of Revenue	$136.6M+3.0%	$132.6M+2.6%	$129.2M-6.1%	$137.5M-11.3%	$155.0M-1.9%	$158.1M-2.0%	$161.2M-3.7%	$167.4M
Gross Profit	$202.4M+3.9%	$194.7M+1.3%	$192.2M-0.4%	$193.1M-0.3%	$193.5M+3.3%	$187.4M+7.2%	$174.9M-0.6%	$175.9M
R&D Expenses	$14.2M-4.6%	$14.9M-8.5%	$16.3M-11.2%	$18.3M+15.6%	$15.8M+12.0%	$14.1M-2.1%	$14.4M-8.9%	$15.9M
SG&A Expenses	$109.2M+7.4%	$101.6M-8.2%	$110.7M-3.8%	$115.1M+8.2%	$106.5M-0.5%	$106.9M-1.2%	$108.2M-2.7%	$111.3M
Operating Income	$67.4M+15.2%	$58.5M+8.6%	$53.9M-24.5%	$71.3M+20.8%	$59.0M+14.2%	$51.7M+30.0%	$39.8M+32.8%	$29.9M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$15.2M+20.9%	$12.6M+13.1%	$11.1M-12.7%	$12.8M+2.7%	$12.4M+14.3%	$10.9M+30.4%	$8.3M+173.7%	$3.0M
Net Income	$44.7M+15.7%	$38.7M+13.7%	$34.0M-41.3%	$58.0M+54.6%	$37.5M+10.8%	$33.8M-11.8%	$38.4M+88.4%	$20.4M
EPS (Diluted)	$0.95+17.3%	$0.81+15.7%	$0.70	N/A	$0.74+12.1%	$0.66-10.8%	$0.74	N/A

HAE Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$2.5B+11.6%	$2.2B+11.9%	$2.0B+7.8%	$1.8B+1.5%	$1.8B+41.6%	$1.3B
Current Assets	$935.0M+21.6%	$768.9M-4.1%	$801.6M+16.5%	$687.8M+0.5%	$684.4M+13.4%	$603.6M
Cash & Equivalents	$306.8M+71.6%	$178.8M-37.4%	$285.7M+32.9%	$214.9M+23.9%	$173.5M+26.3%	$137.3M
Inventory	$365.1M+15.1%	$317.2M+9.7%	$289.2M+4.1%	$277.9M-14.9%	$326.5M+20.8%	$270.3M
Accounts Receivable	$202.7M-1.9%	$206.6M+16.6%	$177.1M+20.9%	$146.5M+10.2%	$132.9M-19.6%	$165.2M
Goodwill	$604.3M+6.9%	$565.1M+21.3%	$465.9M0.0%	$466.1M0.0%	$466.3M+121.4%	$210.7M
Total Liabilities	$1.6B+31.9%	$1.2B+12.6%	$1.1B+4.5%	$1.1B-6.0%	$1.1B+64.3%	$680.0M
Current Liabilities	$578.1M+92.5%	$300.4M+26.8%	$236.9M+31.3%	$180.5M-21.0%	$228.3M-16.9%	$274.8M
Long-Term Debt	$921.2M+15.5%	$797.6M+6.1%	$751.4M-1.5%	$763.1M-0.5%	$767.3M+151.2%	$305.5M
Total Equity	$820.8M-14.5%	$960.0M+11.0%	$864.6M+12.2%	$770.4M+13.8%	$677.1M+15.3%	$587.1M
Retained Earnings	$352.2M-2.3%	$360.5M+26.9%	$284.0M+27.8%	$222.3M+43.8%	$154.6M+96.9%	$78.5M

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Total Assets	$2.5B+2.0%	$2.4B-0.8%	$2.5B+0.5%	$2.5B-3.2%	$2.5B+0.2%	$2.5B-0.6%	$2.5B+15.7%	$2.2B
Current Assets	$943.7M+4.9%	$899.7M-1.5%	$913.2M-2.3%	$935.0M-7.0%	$1.0B+5.2%	$955.9M-2.3%	$978.6M+27.3%	$768.9M
Cash & Equivalents	$363.4M+22.6%	$296.4M+1.2%	$292.9M-4.5%	$306.8M-4.4%	$320.8M+7.2%	$299.3M-13.1%	$344.4M+92.6%	$178.8M
Inventory	$321.2M-4.5%	$336.2M-6.7%	$360.5M-1.3%	$365.1M+1.5%	$359.6M-5.9%	$382.1M+2.2%	$373.8M+17.8%	$317.2M
Accounts Receivable	$195.7M-5.5%	$207.1M+3.1%	$200.8M-0.9%	$202.7M-4.4%	$211.9M-0.7%	$213.5M+6.0%	$201.5M-2.5%	$206.6M
Goodwill	$606.8M+0.1%	$606.1M-0.2%	$607.3M+0.5%	$604.3M-0.2%	$605.3M-1.8%	$616.2M+0.5%	$613.3M+8.5%	$565.1M
Total Liabilities	$1.6B-0.9%	$1.6B+0.8%	$1.6B-3.1%	$1.6B+0.4%	$1.6B-1.3%	$1.6B+0.7%	$1.6B+32.4%	$1.2B
Current Liabilities	$539.9M-1.5%	$548.3M+3.2%	$531.4M-8.1%	$578.1M+128.3%	$253.2M-7.6%	$273.9M+5.3%	$260.1M-13.4%	$300.4M
Long-Term Debt	$920.0M0.0%	$920.4M0.0%	$920.8M0.0%	$921.2M-24.5%	$1.2B0.0%	$1.2B+0.1%	$1.2B+52.8%	$797.6M
Total Equity	$911.5M+7.3%	$849.2M-3.8%	$882.3M+7.5%	$820.8M-9.5%	$906.9M+3.2%	$878.9M-2.9%	$905.4M-5.7%	$960.0M
Retained Earnings	$381.1M+13.3%	$336.3M-5.5%	$356.0M+1.1%	$352.2M-10.2%	$392.2M+6.4%	$368.5M-4.7%	$386.6M+7.3%	$360.5M

HAE Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$181.7M0.0%	$181.8M-33.4%	$273.1M+58.5%	$172.3M+58.3%	$108.8M-31.2%	$158.2M
Capital Expenditures	$39.3M+3.0%	$38.1M-80.1%	$191.3M+98.2%	$96.5M+160.6%	$37.0M-24.0%	$48.8M
Free Cash Flow	$142.4M-0.8%	$143.6M+75.7%	$81.7M+7.9%	$75.8M+5.6%	$71.8M-34.4%	$109.5M
Investing Cash Flow	-$161.9M+49.8%	-$322.4M-124.2%	-$143.8M-66.5%	-$86.3M+79.7%	-$425.4M-644.1%	-$57.2M
Financing Cash Flow	$108.8M+185.2%	$38.2M+138.0%	-$100.4M-537.3%	-$15.7M-104.3%	$367.5M+380.1%	-$131.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$225.0M	$0-100.0%	$75.0M	$0	$0-100.0%	$175.0M

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Operating Cash Flow	$93.6M-16.0%	$111.3M+540.0%	$17.4M-85.1%	$116.6M+166.3%	$43.8M-10.4%	$48.8M+278.0%	-$27.4M-142.8%	$64.1M
Capital Expenditures	$6.3M+26.6%	$5.0M+33.6%	$3.8M-76.0%	$15.6M+83.0%	$8.5M-9.4%	$9.4M+66.8%	$5.7M-15.4%	$6.7M
Free Cash Flow	$87.2M-18.0%	$106.3M+679.3%	$13.6M-86.5%	$100.9M+186.5%	$35.2M-10.6%	$39.4M+219.1%	-$33.1M-157.6%	$57.4M
Investing Cash Flow	-$29.5M+3.3%	-$30.5M+7.7%	-$33.0M-282.9%	$18.0M+203.9%	-$17.4M+25.7%	-$23.4M+83.2%	-$139.2M-966.2%	-$13.1M
Financing Cash Flow	$2.0M+102.7%	-$76.6M-3034.8%	-$2.4M+98.4%	-$151.4M-11074.6%	$1.4M+101.8%	-$74.8M-122.4%	$333.7M+625.5%	-$63.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$0	N/A	N/A	$150.0M	$0	N/A	N/A	$0

HAE Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	55.0%+2.2pp	52.8%+0.2pp	52.6%+1.7pp	50.9%+5.2pp	45.7%-3.3pp	49.0%
Operating Margin	16.3%+3.7pp	12.6%-0.8pp	13.4%+5.2pp	8.1%-2.2pp	10.3%-0.2pp	10.5%
Net Margin	12.3%+3.3pp	9.0%-0.9pp	9.9%+5.5pp	4.4%-4.8pp	9.1%+1.4pp	7.7%
Return on Equity	20.4%+8.2pp	12.3%-1.1pp	13.4%+7.7pp	5.6%-6.1pp	11.7%-1.3pp	13.0%
Return on Assets	6.8%+1.5pp	5.3%-0.5pp	5.9%+3.5pp	2.4%-2.0pp	4.4%-1.6pp	6.0%
Current Ratio	1.62-0.9	2.56-0.8	3.38-0.4	3.81+0.8	3.00+0.8	2.20
Debt-to-Equity	1.12+0.3	0.83-0.0	0.87-0.1	0.99-0.1	1.13+0.6	0.52
FCF Margin	10.5%-0.5pp	11.0%+4.0pp	7.0%-0.6pp	7.6%-0.6pp	8.2%-2.8pp	11.1%

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Gross Margin	59.7%+0.2pp	59.5%-0.3pp	59.8%+1.4pp	58.4%+2.9pp	55.5%+1.3pp	54.3%+2.2pp	52.0%+0.8pp	51.2%
Operating Margin	19.9%+2.0pp	17.9%+1.1pp	16.8%-4.8pp	21.6%+4.6pp	16.9%+2.0pp	15.0%+3.1pp	11.8%+3.1pp	8.7%
Net Margin	13.2%+1.4pp	11.8%+1.2pp	10.6%-7.0pp	17.5%+6.8pp	10.8%+1.0pp	9.8%-1.6pp	11.4%+5.5pp	5.9%
Return on Equity	4.9%+0.3pp	4.6%+0.7pp	3.9%-3.2pp	7.1%+2.9pp	4.1%+0.3pp	3.9%-0.4pp	4.2%+2.1pp	2.1%
Return on Assets	1.8%+0.2pp	1.6%+0.2pp	1.4%-1.0pp	2.4%+0.9pp	1.5%+0.1pp	1.3%-0.2pp	1.5%+0.6pp	0.9%
Current Ratio	1.75+0.1	1.64-0.1	1.72+0.1	1.62-2.4	3.97+0.5	3.49-0.3	3.76+1.2	2.56
Debt-to-Equity	1.01-0.1	1.08+0.0	1.04-0.1	1.12-0.2	1.34-0.0	1.39+0.0	1.35+0.5	0.83
FCF Margin	25.7%-6.8pp	32.5%+28.2pp	4.2%-26.3pp	30.5%+20.4pp	10.1%-1.3pp	11.4%+21.2pp	-9.8%-26.6pp	16.7%

Similar Companies

Inspire Medical INSP

$1.6B

Alphatec Hldgs Inc ATEC

$1.6B

Integer Hldgs Corp ITGR

$3.0B

Livanova Plc LIVN

$3.5B

Procept Biorobotics Corp PRCT

$1.4B

Frequently Asked Questions

What is Haemonetics Corp Mass's annual revenue?

Haemonetics Corp Mass (HAE) reported $1.4B in total revenue for fiscal year 2025. This represents a 4.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Haemonetics Corp Mass's revenue growing?

Haemonetics Corp Mass (HAE) revenue grew by 4% year-over-year, from $1.3B to $1.4B in fiscal year 2025.

Is Haemonetics Corp Mass profitable?

Yes, Haemonetics Corp Mass (HAE) reported a net income of $167.7M in fiscal year 2025, with a net profit margin of 12.3%.

What is Haemonetics Corp Mass's EBITDA?

Haemonetics Corp Mass (HAE) had EBITDA of $337.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Haemonetics Corp Mass have?

As of fiscal year 2025, Haemonetics Corp Mass (HAE) had $306.8M in cash and equivalents against $921.2M in long-term debt.

What is Haemonetics Corp Mass's gross margin?

Haemonetics Corp Mass (HAE) had a gross margin of 55.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Haemonetics Corp Mass's operating margin?

Haemonetics Corp Mass (HAE) had an operating margin of 16.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Haemonetics Corp Mass's net profit margin?

Haemonetics Corp Mass (HAE) had a net profit margin of 12.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Haemonetics Corp Mass's return on equity (ROE)?

Haemonetics Corp Mass (HAE) has a return on equity of 20.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Haemonetics Corp Mass's free cash flow?

Haemonetics Corp Mass (HAE) generated $142.4M in free cash flow during fiscal year 2025. This represents a -0.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Haemonetics Corp Mass's operating cash flow?

Haemonetics Corp Mass (HAE) generated $181.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Haemonetics Corp Mass's total assets?

Haemonetics Corp Mass (HAE) had $2.5B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Haemonetics Corp Mass's capital expenditures?

Haemonetics Corp Mass (HAE) invested $39.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Haemonetics Corp Mass spend on research and development?

Haemonetics Corp Mass (HAE) invested $62.7M in research and development during fiscal year 2025.

Does Haemonetics Corp Mass buy back shares?

Yes, Haemonetics Corp Mass (HAE) spent $225.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Haemonetics Corp Mass have outstanding?

Haemonetics Corp Mass (HAE) had 48M shares outstanding as of fiscal year 2025.

What is Haemonetics Corp Mass's current ratio?

Haemonetics Corp Mass (HAE) had a current ratio of 1.62 as of fiscal year 2025, which is generally considered healthy.

What is Haemonetics Corp Mass's debt-to-equity ratio?

Haemonetics Corp Mass (HAE) had a debt-to-equity ratio of 1.12 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Haemonetics Corp Mass's return on assets (ROA)?

Haemonetics Corp Mass (HAE) had a return on assets of 6.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Haemonetics Corp Mass's Altman Z-Score?

Haemonetics Corp Mass (HAE) has an Altman Z-Score of 2.20, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Haemonetics Corp Mass's Piotroski F-Score?

Haemonetics Corp Mass (HAE) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Haemonetics Corp Mass's earnings high quality?

Haemonetics Corp Mass (HAE) has an earnings quality ratio of 1.08x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Haemonetics Corp Mass cover its interest payments?

Haemonetics Corp Mass (HAE) has an interest coverage ratio of 6.2x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Haemonetics Corp Mass?

Haemonetics Corp Mass (HAE) scores 52 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.